

4. (Amended) A method as claimed in [any one of claims 1 to 3] claim 1, wherein the peptide-specific effector T-cells are CD8+ or CD4+ cells and the cytokine is IFN- γ .

5. (Amended) A method as claimed in [any one of claims 1 to 4] claim 1, wherein the peptide presented to the T-cells is 7 - 15 amino acid residues in length.

6. (Amended) A method as claimed in [any one of claims 1 to 5] claim 1, wherein the resulting fluid mixture is incubated under non-sterile conditions.

7. (Amended) A method as claimed in [any one of claims 1 to 6] claim 1, wherein the peptide is a known epitope.

8. (Amended) A method as claimed in [any one of claims 1 to 7] claim 1, wherein the fluid contains fresh T-cells that have not been cultured *in vitro*.

9. (Amended) A method as claimed in [any one of claims 1 to 8] claim 1, wherein incubation is continued for a time of 4 to 24 hours.

10. (Amended) A method as claimed in [any one of claims 1 to 9] claim 1, wherein the peptide or peptide-containing moiety is added to provide a concentration in the fluid of up to 5 μ M.
11. (Amended) A method as claimed in [any one of claims 1 to 10] claim 1, wherein the peptide or peptide-containing moiety added to the fluid is in uncombined form.)
12. (Amended) A method as claimed in [any one of claims 1 to 11] claim 1, wherein the T-cells are taken from a patient known to be suffering, or to have suffered from, infection with a pathogen.
13. (Amended) A method as claimed in [any one of claims 1 to 12] claim 1, performed to monitor progress of HIV infection.
14. (Amended) A method as claimed in [any one of claims 1 to 12] claim 1, performed to monitor the effect of a vaccine.
15. (Amended) A method as claimed in [any one of claims 1 to 12] claim 1, performed to determine a pathogen-derived epitope targeted by CD4+ or CD8+ T cells.